Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Marco Aguggia, Davide Bertuzzo et al.|Journal of Neurology|2024Cited by 37
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo et al.|Journal of Neurology|2024Cited by 4
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giacomo Querzola, Giulia Fiorentini et al.|The Journal of Headache and Pain|2025Cited by 4
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 studyPiero Barbanti, Alfonso Coppola, Gabriella Egeo et al.|The Journal of Headache and Pain|2026Cited by 0